TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06501248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triticum Aestivum
Description: The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
Study: NCT05423249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
Study: NCT06501248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (calcined magnesia)
Description: The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
Study: NCT05546372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobiliary radiofrequency ablation (eRFA)
Description: Intraductal radiofrequency ablation of tumor prior to stent placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uncovered self-expanding metal stent (uSEMS)
Description: Intraductal placement of uncovered metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncovered self-expanding metal stent (uSEMS)
Description: Intraductal placement of uncovered metal stent
Study: NCT04739215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Dapagliflozin 10 mg / day oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo capsule daily oral
Study: NCT04951544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LetSync v1.0
Description: Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LetSync v2.0
Description: LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
Study: NCT06105645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIXI Medical Microdeep® Micro- Macro Depth electrodes
Description: It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard electrodes
Description: Standard electrodes used usually during the SEEG
Study: NCT06374979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
Study: NCT05423249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prenatal
Description: Oral prenatal vitamin once daily for both groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prenatal
Description: Oral prenatal vitamin once daily for both groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docusate Sodium
Description: Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium
Description: Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500Mg Tab
Description: Oral ascorbic acid 500 mg daily, to improve absorption of oral iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo pill once daily
Study: NCT05831891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib combined with Serplulimab
Description: Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
Study: NCT06455995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEPTH
Description: All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEPTH
Description: All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DEPTH
Description: All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEPTH-Morning
Description: Morning will also have time-based energy intake goals of 70% of kcal within the first 6 hrs of the eating window and 30% of kcal within the last 6 hrs of the eating window (a morning-loaded energy distribution).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEPTH-Evening
Description: Evening will also have time-based energy intake goals of 30% of kcal within the first 6 hrs of the eating window and 70% of kcal within the last 6 hrs of the eating window (an evening-loaded energy distribution).
Study: NCT04847622

Intervention type: DRUG
Intervention: Remdesivir
Description: treated with Remdesivir
Study: NCT05750004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided immediate implant placement
Description: Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
Study: NCT06570642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Goals mHealth Intervention
Description: On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
Study: NCT05212090

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOS X-Ray
Description: Repeated AP Pelvis x-ray and Lateral Lumbar EOS x-ray

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOS X-Ray
Description: Repeated AP Pelvis x-ray and Lateral Lumbar EOS x-ray
Study: NCT05220124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)
Description: 420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.
Study: NCT06192394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: Patients will be asked to chew xylitol gum for 20 minutes every 2 hours (17.00-19.00, 19.00-21.00, 21.00-23.00) after drinking the X-M Diet syrup prescribed the day before the colonoscopy procedure. After the enema is given on the day of the colonoscopy, they will be asked to chew gum for 20 minutes every 2 hours until one hour before the scheduled procedure time. Xylitol is a naturally occurring five-carbon sugar alcohol (C5H12O5) found in fruits and vegetables such as plums, strawberries, cauliflower, and pumpkin. It is similar in taste to sucrose but contains 40% fewer calories than other carbohydrates (1 gram of xylitol = 2.4 calories). Xylitol has positive effects on dental health and may also have beneficial impacts on other systems such as immunity, respiratory, and digestive systems. Since xylitol is not digested by human enzymes, it has a laxative effect. In the study, sugar-free gum with xylitol will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Exercise
Description: Patients will be given a pedometer to count their steps and will be asked to walk at least 3000 steps before the colonoscopy procedure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients will undergo standard bowel preparation determined by the hospital.
Study: NCT05633056

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence support intevention
Description: Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence support intevention
Description: Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence support intevention
Description: Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.
Study: NCT06570083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Exercise Support
Description: Participants receive three months of personalized support via WeChat, including tailored exercise recommendations, motivational messages, and educational content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help physical activity booklet
Description: Participants receive a self-help booklet to promote physical activity among the elderly. The booklet will include guidelines for safe and effective exercises, tips for staying motivated, and information on the health benefits of regular physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help physical activity booklet
Description: Participants receive a self-help booklet to promote physical activity among the elderly. The booklet will include guidelines for safe and effective exercises, tips for staying motivated, and information on the health benefits of regular physical activity.
Study: NCT05939622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural and functional MRI
Description: MRI using a Siemens MAGNETOM Prisma 3T scanner before and after a course of therapy, using resting state fMRI and with cognitive paradigm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Structural and functional MRI
Description: MRI using a Siemens MAGNETOM Prisma 3T scanner before and after a course of therapy, using resting state fMRI and with cognitive paradigm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl methyl hydroxypyridine succinate + Meldonium
Description: Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was used in the same way
Study: NCT06377644

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping is a physiotherapy method employed to provide support and stability to muscles and joints while allowing freedom of movement (ROM). The elastic nature of kinesio tape closely resembles that of human skin. After application, kinesio tape rebounds, generating a pulling force that acts as the primary stabilizer for the specific area. Physiotherapy treatments often involve a combination of stretching and strengthening exercises, along with electrotherapy modalities. Additionally, Joint mobilization is a form of passive movement in a broad spectrum of exercise used to treat painful and stiff synovial joints.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dry Needling
Description: Dry needling is a minimally invasive technique involving the use of a single filament or acupuncture needle to penetrate painful soft tissue areas. From a neurophysiological standpoint, Dry Needling might stimulate A-delta nerve fibers (group III), which could activate inhibitory dorsal horn interneurons containing enkephalin, leading to pain suppression and relief through opioid mechanisms. (DN) may affect microcirculation. Numerous studies have shown that inserting needles into muscles can increase blood flow in both the skin and the muscle in the treated area. It can lead to an immediate reduction in local and referred pains, as well as enhance range of motion (ROM) and correct muscle activity patterns.
Study: NCT04487860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS012
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS012
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS012
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS012
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT05183958

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy group
Description: Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 \>60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 4 cycles for combined therapy. Camrelizumab maintenance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camrelizumab
Description: 4 cycles for combined therapy. Camrelizumab maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 4 cycles for combined therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: 4 cycles for combined therapy.
Study: NCT05523362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom continuous glucose monitor
Description: The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.
Study: NCT05955378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSR Ankle
Description: This is the experimental ankle component used in the overall prosthetic intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predicate Ankle
Description: This is the participant's prescribed ankle/foot complex used in the overall prosthetic intervention.
Study: NCT04926766

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam radiotherapy using IMRT technique
Description: 2600cGy/ 5 fractions / 1 weeks to ipsilateral whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
Study: NCT06156943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: individualized goal-directed fluid therapy by Starling device
Description: For patients in optimized group, fluids will be managed by Starling device during the lung resection surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: group managed by standard of care
Description: Patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols
Study: NCT05578612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Spanning Bridge Plate Fixation
Description: Dorsal spanning bridge fixation will be performed by board-certified orthopedic surgeons per standard technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Spanning Bridge Plate Fixation
Description: Dorsal spanning bridge fixation will be performed by board-certified orthopedic surgeons per standard technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Spanning Bridge Plate Removal
Description: Dorsal spanning bridge removal will be performed by board-certified orthopedic surgeons per standard technique.
Study: NCT06502561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol meglumine
Description: Aramchol meglumine is a salt form of Aramchol free acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol meglumine
Description: Aramchol meglumine is a salt form of Aramchol free acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol meglumine
Description: Aramchol meglumine is a salt form of Aramchol free acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol free acid
Description: Aramchol free acid is a fatty acid-bile acid conjugate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol free acid
Description: Aramchol free acid is a fatty acid-bile acid conjugate
Study: NCT05578612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Spanning Bridge Plate Removal
Description: Dorsal spanning bridge removal will be performed by board-certified orthopedic surgeons per standard technique.
Study: NCT04971044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH
Description: Multi-Level Behavioral Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School Readiness Intervention
Description: Multi-Level Language and School Readiness Intervention (Control Group)
Study: NCT06478173

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training will be performed as supervised small sided soccer games (3v3 to 7v7) 3 times a week for 14 weeks. Each session will last \~1 hour. Patients allocated to soccer training will undergo a ramp-up phase consisting of walking soccer training during weeks 1 and 2, after which normal soccer training will be applied from weeks 3 to 14.
Study: NCT05650450

Intervention type: DEVICE
Intervention: DES+DCB
Description: Hybrid approach is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES for a de novo long (\>38 mm) lesion (located in the larger, more proximal part of the vessel -reference vessel diameter -RVD \>2.75 mm-) and DCB inflation for a concomitant and contiguous de novo small vessel disease (distally located with RVD ≤2.75 mm ≥ 2.0 mm)
Study: NCT05547373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infection prevention and control (IPC)
Description: The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
Study: NCT05036005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontruzant
Description: All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
Study: NCT05501158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations